Pancreatic Cancer Research

ResearcherNanjing Drum Tower HospitalActive in the last 2 years

Shanshan Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-1101-2698; OpenAlex author ID A5045531895. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 5 papers · 2022: 2 papers · 2023: 4 papers · 2024: none · 2025: 3 papers

Papers 18

  1. Clinical characteristics of pancreatic cancer presenting with acute pancreatitis: a propensity-matched cohort study. Last author DOI 10.1007/s00464-025-11654-z↗
  2. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  3. Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgica… Co-author DOI 10.1080/07853890.2025.2541314↗
  4. Cinchonine-induced cell death in pancreatic cancer cells by downregulating RRP15. Co-author DOI 10.1002/cbin.11987↗
  5. Protein tyrosine phosphatase nonreceptor type 2 exerts antimetastatic functions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mc.23554↗
  6. Lithium chloride induces apoptosis by activating endoplasmic reticulum stress in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2023.101792↗
  7. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-023-40727-7↗
  8. Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations. Co-author DOI 10.1038/s41388-022-02328-4↗
  9. Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic niches to inhibit liver metastasis. Co-author DOI 10.1039/d2bm00770c↗
  10. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  11. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent man… Last author DOI 10.1186/s13148-021-01016-6↗
  12. Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer. Co-author DOI 10.2147/cmar.s330473↗
  13. PPARγ/SOD2 Protects Against Mitochondrial ROS-Dependent Apoptosis via Inhibiting ATG4D-Mediated Mitophagy to Promote Pancreatic Cancer Proliferation. Last author DOI 10.3389/fcell.2021.745554↗
  14. GPRC5A: An emerging prognostic biomarker for predicting malignancy of Pancreatic Cancer based on bioinformatics analysis. Co-author DOI 10.7150/jca.52578↗
  15. CircRHOT1 mediated cell proliferation, apoptosis and invasion of pancreatic cancer cells by sponging miR-125a-3p. Co-author DOI 10.1111/jcmm.15572↗
  16. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Last author DOI 10.3389/fonc.2020.00915↗
  17. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2018.07.003↗
  18. The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail. Co-author DOI 10.1097/mpa.0000000000000418↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoping Zou · 15 shared papers, 2015–2025 · strength 1.89
  2. Ying Lv · 9 shared papers, 2021–2025 · strength 1.30
  3. Shu Zhang · 8 shared papers, 2020–2023 · strength 1.02
  4. Hongzhen Li · 6 shared papers, 2020–2025 · strength 0.77
  5. Shuang Nie · 6 shared papers, 2018–2025 · strength 0.74
  6. Yixuan Zhang · 4 shared papers, 2021–2023 · strength 0.57
  7. Bo Kong · 6 shared papers, 2018–2021 · strength 0.57
  8. Xuetian Qian · 4 shared papers, 2020–2021 · strength 0.50
  9. Song Zhang · 3 shared papers, 2015–2025 · strength 0.45
  10. Helmut Friess · 4 shared papers, 2018–2025 · strength 0.44
  11. Hao Wu · 3 shared papers, 2022–2023 · strength 0.42
  12. Yudong Qiu · 2 shared papers, 2025 · strength 0.40
  13. Hao Cheng · 2 shared papers, 2025 · strength 0.40
  14. Lei Wang · 3 shared papers, 2020–2023 · strength 0.35
  15. Zhiheng Zhang · 3 shared papers, 2018–2025 · strength 0.33
  16. Christoph W. Michalski · 3 shared papers, 2018–2025 · strength 0.33
  17. Jorg H. Kleeff · 3 shared papers, 2018–2025 · strength 0.33
  18. Zipeng Lu · 2 shared papers, 2020–2025 · strength 0.28
  19. Helmut Frieß · 2 shared papers, 2020–2025 · strength 0.27
  20. Maximilian Reichert · 2 shared papers, 2021–2025 · strength 0.27
  21. Ying Lv · 3 shared papers, 2015–2021 · strength 0.27
  22. Chao Yan · 2 shared papers, 2022–2023 · strength 0.26
  23. Siqi Zhou · 2 shared papers, 2021–2022 · strength 0.25
  24. Huizi Sha · 1 shared paper, 2025 · strength 0.21
  25. Juan Du · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.